Figure 1 - Frequency Distribution of All VAERS LYMErix® Reports by Age at Onset of Adverse Event

1/25/01


Click here to start


Table of Contents

Figure 1 - Frequency Distribution of All VAERS LYMErix® Reports by Age at Onset of Adverse Event

Figure 2- Frequency Distribution of All VAERS LYMErix® Reports by Time to Onset of Adverse Event

Figure 3 - Frequency Distribution of All VAERS LYMErix® Reports by Dose

Table 1 - Ten Most Common VAERS LYMErix® Adverse Event Coding Terms

Table 2 - Summary of Serious Reports after LYMErix® Reported to VAERS

Figure 4 - Frequency Distribution of VAERS LYMErix® Rheumatoid Arthritis Reports by Time to Onset and Dose

Figure 5 - Frequency Distribution of VAERS LYMErix® Arthritis Reports by Time to Onset and Dose

Table 3 - Clinical Characteristics of VAERS LYMErix® Reports Coded Arthritis, Arthrosis, and Rheumatoid Arthritis (RA)

Figure 6 - Frequency Distribution of VAERS LYMErix® “Arthritis” Reports Indicating Joint Swelling by Time to Onset and Dose

Figure 7 - Frequency Distribution of VAERS LYMErix® Reports of Facial Paralysis by Time to Onset

Figure 8 - Frequency Distribution of VAERS LYMErix® Reports of Hypersensitivity by Time to Onset

Table 4 - Ten Most Common VAERS Coding Terms Following LYMErix® for People with a Self-Reported History of Lyme Disease

Author: CBER